The Experts below are selected from a list of 42210 Experts worldwide ranked by ideXlab platform
Teri E Klein - One of the best experts on this subject based on the ideXlab platform.
-
the clinical Pharmacogenetics implementation consortium 10 years later
Clinical Pharmacology & Therapeutics, 2020Co-Authors: Mary V Relling, James M Hoffman, Teri E Klein, Michelle Whirlcarrillo, Roseann S Gammal, Kelly E. CaudleAbstract:In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC, www.cpicpgx.org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB, http://www.pharmgkb.org) and the National Institutes of Health (NIH), was created to provide freely available, evidence-based, peer-reviewed, and updated pharmacogenetic clinical practice guidelines. To date, CPIC has published 23 guidelines (of which 11 have been updated), covering 19 genes and 46 drugs across several therapeutic areas. CPIC also now provides additional resources to facilitate the implementation of Pharmacogenetics into routine clinical practice and the electronic health record. Furthermore, since its inception, CPIC's interactions with other resources, databases, websites, and genomic communities have grown. The purpose of this paper is to highlight the progress of CPIC over the past 10 years.
-
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Genetics in medicine : official journal of the American College of Medical Genetics, 2016Co-Authors: Kelly E. Caudle, Josh F Peterson, Robert R. Freimuth, Stuart A. Scott, Henry M. Dunnenberger, Jonathan D. Burlison, Michelle Whirl-carrillo, Heidi L. Rehm, Marc S. Williams, Teri E KleinAbstract:Reporting and sharing pharmacogenetic test results across clinical laboratories and electronic health records is a crucial step toward the implementation of clinical Pharmacogenetics, but allele function and phenotype terms are not standardized. Our goal was to develop terms that can be broadly applied to characterize pharmacogenetic allele function and inferred phenotypes. Terms currently used by genetic testing laboratories and in the literature were identified. The Clinical Pharmacogenetics Implementation Consortium (CPIC) used the Delphi method to obtain a consensus and agree on uniform terms among pharmacogenetic experts. Experts with diverse involvement in at least one area of Pharmacogenetics (clinicians, researchers, genetic testing laboratorians, Pharmacogenetics implementers, and clinical informaticians; n = 58) participated. After completion of five surveys, a consensus (>70%) was reached with 90% of experts agreeing to the final sets of pharmacogenetic terms. The proposed standardized pharmacogenetic terms will improve the understanding and interpretation of pharmacogenetic tests and reduce confusion by maintaining consistent nomenclature. These standard terms can also facilitate pharmacogenetic data sharing across diverse electronic health care record systems with clinical decision support. Genet Med 19 2, 215–223.
-
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Alan R Shuldiner, Naveen Luke Pereira, Josh F Peterson, Julie A. Johnson, Dan M Roden, Wolfgang Sadée, K Hicks, Mary V Relling, Robert R. Freimuth, Teri E KleinAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience. Clinical Pharmacology & Therapeutics (2013); 94 2, 207–210. doi:10.1038/clpt.2013.59
-
PHARMGKB: THE Pharmacogenetics KNOWLEDGE BASE
Nucleic acids research, 2002Co-Authors: Micheal Hewett, Russ B Altman, Diane E. Oliver, Daniel L. Rubin, Katrina L. Easton, Joshua M. Stuart, Teri E KleinAbstract:The Pharmacogenetics Knowledge Base (PharmGKB; http://www.pharmgkb.org/) contains genomic, phenotype and clinical information collected from ongoing pharmacogenetic studies. Tools to browse, query, download, submit, edit and process the information are available to registered research network members. A subset of the tools is publicly available. PharmGKB currently contains over 150 genes under study, 14 Coriell populations and a large ontology of Pharmacogenetics concepts. The pharmacogenetic concepts and the experimental data are interconnected by a set of relations to form a knowledge base of information for pharmacogenetic researchers. The information in PharmGKB, and its associated tools for processing that information, are tailored for leading-edge Pharmacogenetics research. The PharmGKB project was initiated in April 2000 and the first version of the knowledge base went online in February 2001.
Mary V Relling - One of the best experts on this subject based on the ideXlab platform.
-
the clinical Pharmacogenetics implementation consortium 10 years later
Clinical Pharmacology & Therapeutics, 2020Co-Authors: Mary V Relling, James M Hoffman, Teri E Klein, Michelle Whirlcarrillo, Roseann S Gammal, Kelly E. CaudleAbstract:In 2009, the Clinical Pharmacogenetics Implementation Consortium (CPIC, www.cpicpgx.org), a shared project between Pharmacogenomics Knowledge Base (PharmGKB, http://www.pharmgkb.org) and the National Institutes of Health (NIH), was created to provide freely available, evidence-based, peer-reviewed, and updated pharmacogenetic clinical practice guidelines. To date, CPIC has published 23 guidelines (of which 11 have been updated), covering 19 genes and 46 drugs across several therapeutic areas. CPIC also now provides additional resources to facilitate the implementation of Pharmacogenetics into routine clinical practice and the electronic health record. Furthermore, since its inception, CPIC's interactions with other resources, databases, websites, and genomic communities have grown. The purpose of this paper is to highlight the progress of CPIC over the past 10 years.
-
the pharmacogenomics research network translational Pharmacogenetics program overcoming challenges of real world implementation
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Naveen Luke Pereira, Josh F Peterson, Dan M Roden, Wolfgang Sadée, K Hicks, Alan R Shuldiner, Mary V Relling, Robert R. Freimuth, Julie A. JohnsonAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience.
-
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Alan R Shuldiner, Naveen Luke Pereira, Josh F Peterson, Julie A. Johnson, Dan M Roden, Wolfgang Sadée, K Hicks, Mary V Relling, Robert R. Freimuth, Teri E KleinAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience. Clinical Pharmacology & Therapeutics (2013); 94 2, 207–210. doi:10.1038/clpt.2013.59
-
development and implementation of a pharmacist managed clinical Pharmacogenetics service
American Journal of Health-system Pharmacy, 2011Co-Authors: Kristine R Crews, Shane J Cross, John N Mccormick, Donald K Baker, Alejandro R Molinelli, Richard Mullins, Mary V Relling, James M HoffmanAbstract:Purpose The development and implementation of a pharmacist-managed clinical Pharmacogenetics service are described. Summary A pharmacist-managed clinical Pharmacogenetics service was designed and implemented at an academic specialty hospital to provide clinical pharmacogenetic testing for gene products important to the pharmacodynamics of medications used in the hospital’s patients. A series of accredited educational seminars were conducted for our pharmacists to establish competencies in providing pharmacogenetic consults for the genes to be tested by the clinical Pharmacogenetics service. The service was modeled after and integrated with an already-established clinical pharmacokinetics service. A steering committee was formed to evaluate the use of available tests, new evidence for implementation of additional tests, and other service quality metrics. All clinical pharmacogenetic test results are first reported to one of the pharmacists, who reviews the result and provides a written consultation. The consultation includes an interpretation of the result and recommendations for any indicated changes to therapy. In 2009, 136 clinical pharmacogenetic tests were performed. The service has been met with positive clinician feedback. The successful implementation of this service highlights the leadership role that pharmacists can take in moving Pharmacogenetics from research to patient care. Conclusion The development of and experience with a pharmacist-managed clinical Pharmacogenetics service are described. The program’s success has depended on collaboration between the clinical laboratory and pharmacists, and pharmacists’ pharmacogenetic recommendations have been well accepted by prescribers.
Alan R Shuldiner - One of the best experts on this subject based on the ideXlab platform.
-
the pharmacogenomics research network translational Pharmacogenetics program overcoming challenges of real world implementation
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Naveen Luke Pereira, Josh F Peterson, Dan M Roden, Wolfgang Sadée, K Hicks, Alan R Shuldiner, Mary V Relling, Robert R. Freimuth, Julie A. JohnsonAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience.
-
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Alan R Shuldiner, Naveen Luke Pereira, Josh F Peterson, Julie A. Johnson, Dan M Roden, Wolfgang Sadée, K Hicks, Mary V Relling, Robert R. Freimuth, Teri E KleinAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience. Clinical Pharmacology & Therapeutics (2013); 94 2, 207–210. doi:10.1038/clpt.2013.59
Josh F Peterson - One of the best experts on this subject based on the ideXlab platform.
-
the pharmacogenomics research network translational Pharmacogenetics program outcomes and metrics of pharmacogenetic implementations across diverse healthcare systems
Clinical Pharmacology & Therapeutics, 2017Co-Authors: Jasmine A Luzum, Josh F Peterson, Ruth E Pakyz, Amanda R Elsey, Cyrine E Haidar, Michelle Whirlcarrillo, Samuel K Handelman, Kathleen Palmer, Jill M Pulley, Marc BellerAbstract:Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of Pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the National Institutes of Health (NIH) Pharmacogenomics Research Network was established in 2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US healthcare systems, with the goal to disseminate real-world solutions for the barriers to clinical pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementation metrics through June 2015, including gene-drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, educational, financial, and informatics), which may inform healthcare systems seeking to implement their own pharmacogenetic testing programs.
-
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Genetics in medicine : official journal of the American College of Medical Genetics, 2016Co-Authors: Kelly E. Caudle, Josh F Peterson, Robert R. Freimuth, Stuart A. Scott, Henry M. Dunnenberger, Jonathan D. Burlison, Michelle Whirl-carrillo, Heidi L. Rehm, Marc S. Williams, Teri E KleinAbstract:Reporting and sharing pharmacogenetic test results across clinical laboratories and electronic health records is a crucial step toward the implementation of clinical Pharmacogenetics, but allele function and phenotype terms are not standardized. Our goal was to develop terms that can be broadly applied to characterize pharmacogenetic allele function and inferred phenotypes. Terms currently used by genetic testing laboratories and in the literature were identified. The Clinical Pharmacogenetics Implementation Consortium (CPIC) used the Delphi method to obtain a consensus and agree on uniform terms among pharmacogenetic experts. Experts with diverse involvement in at least one area of Pharmacogenetics (clinicians, researchers, genetic testing laboratorians, Pharmacogenetics implementers, and clinical informaticians; n = 58) participated. After completion of five surveys, a consensus (>70%) was reached with 90% of experts agreeing to the final sets of pharmacogenetic terms. The proposed standardized pharmacogenetic terms will improve the understanding and interpretation of pharmacogenetic tests and reduce confusion by maintaining consistent nomenclature. These standard terms can also facilitate pharmacogenetic data sharing across diverse electronic health care record systems with clinical decision support. Genet Med 19 2, 215–223.
-
the pharmacogenomics research network translational Pharmacogenetics program overcoming challenges of real world implementation
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Naveen Luke Pereira, Josh F Peterson, Dan M Roden, Wolfgang Sadée, K Hicks, Alan R Shuldiner, Mary V Relling, Robert R. Freimuth, Julie A. JohnsonAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience.
-
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Alan R Shuldiner, Naveen Luke Pereira, Josh F Peterson, Julie A. Johnson, Dan M Roden, Wolfgang Sadée, K Hicks, Mary V Relling, Robert R. Freimuth, Teri E KleinAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience. Clinical Pharmacology & Therapeutics (2013); 94 2, 207–210. doi:10.1038/clpt.2013.59
Julie A. Johnson - One of the best experts on this subject based on the ideXlab platform.
-
the pharmacogenomics research network translational Pharmacogenetics program overcoming challenges of real world implementation
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Naveen Luke Pereira, Josh F Peterson, Dan M Roden, Wolfgang Sadée, K Hicks, Alan R Shuldiner, Mary V Relling, Robert R. Freimuth, Julie A. JohnsonAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience.
-
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation.
Clinical Pharmacology & Therapeutics, 2013Co-Authors: Alan R Shuldiner, Naveen Luke Pereira, Josh F Peterson, Julie A. Johnson, Dan M Roden, Wolfgang Sadée, K Hicks, Mary V Relling, Robert R. Freimuth, Teri E KleinAbstract:The pace of discovery of potentially actionable pharmacogenetic variants has increased dramatically in recent years. However, the implementation of this new knowledge for individualized patient care has been slow. The Pharmacogenomics Research Network (PGRN) Translational Pharmacogenetics Program seeks to identify barriers and develop real-world solutions to implementation of evidence-based pharmacogenetic tests in diverse health-care settings. Dissemination of the resulting toolbox of “implementation best practices” will prove useful to a broad audience. Clinical Pharmacology & Therapeutics (2013); 94 2, 207–210. doi:10.1038/clpt.2013.59